Indian Council of Medical Research has said that COVID-19 vaccine Covaxin has equivalent immunogenicity against the UK-variant and circulating strains of SARS-Cov2 in India. <br />''<br />''<br />''<span style="color: #222222;">Covaxin is developed by Bharat Biotech in collaboration with ICMR. The UK-variant of SARS-Cov-2 with its all signature mutations were isolated and cultured in the world successfully for the first time at ICMR-NIV which was used for testing.</span><br />